Your browser doesn't support javascript.
loading
Does 5 + 5 Equal Better Radiation Treatment Plans in Head and Neck Cancers?
Corkum, Mark T; Mitchell, Sylvia; Venkatesan, Varagur; Read, Nancy; Warner, Andrew; Palma, David A.
Afiliación
  • Corkum MT; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
  • Mitchell S; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
  • Venkatesan V; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
  • Read N; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
  • Warner A; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
  • Palma DA; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
Adv Radiat Oncol ; 4(4): 683-688, 2019.
Article en En | MEDLINE | ID: mdl-31673661
PURPOSE: Accurate contouring in head and neck cancer (HNC) is critical. International consensus guidelines recommend the 5 + 5 mm rule for expansions around the primary tumor, wherein high- and low-dose clinical target volumes (CTV-P1 and CTV-P2, respectively) are created using successive 5 mm expansions on the gross tumor volume. To our knowledge, the necessity of a low-dose CTV-P2 has never been assessed; therefore, we evaluated the dosimetric impact of adding a CTV-P2 expansion using the 5 + 5 mm rule compared with contouring with a high-dose CTV-P1 alone. METHODS AND MATERIALS: A retrospective study of clinically delivered (chemo)radiation therapy treatment plans for HNC was conducted. All patients were treated with 70 Gy in 35 fractions using volumetric modulated arc therapy in a single phase. CTV-P2 was retrospectively contoured per guidelines as a 5 mm expansion on CTV-P1 from the clinical plan, carving off specified barriers to spread. We used a 5 mm planning target volume (PTV) expansion. Our primary outcome was whether 95% of the volume of the PTV for the CTV-P2 contour (ie, PTV-P2) received at least 56 Gy. To assess dose falloff, the coverage of a PTV ring structure was created by subtracting PTV-P1 from PTV-P2. RESULTS: Twenty-seven patients from 4 HNC subsites (base of tongue, tonsil, hypopharynx, and supraglottic larynx) were included. In all 108 treatment plans, at least 95% of the PTV-P2 structure received at least 56 Gy. The minimum volume of the PTV-P2 structure receiving at least 56 Gy was 97.4%. Eight of 108 treatment plans had borderline coverage of the PTV ring substructure alone. CONCLUSIONS: Adding a CTV-P2 structure using the 5 + 5 mm rule had no dosimetric impact, adds contouring time, adds treatment planning complexity, and could potentially introduce errors. The 5 + 5 mm rule may have value in other settings, such as when smaller PTV margins are used, and warrants further evaluation with prospective or randomized studies.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Observational_studies Idioma: En Revista: Adv Radiat Oncol Año: 2019 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Observational_studies Idioma: En Revista: Adv Radiat Oncol Año: 2019 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos